This website has been produced and funded by Novo Nordisk and is intended for adult patients in
the United Kingdom who have been prescribed Wegovy®▼ (semaglutide injection). Side effect reporting
information can be found in the footer of this page.
Key information about Wegovy®▼(semaglutide injection)
Now that you have been prescribed Wegovy®, you may have questions about your treatment. This page provides answers to some of those key questions.
What is Wegovy®?
This image is for illustrative purposes only and does not reflect the actual size of the pen. The image shown above is of the 2.4 mg Wegovy® FlexTouch® pen.
Wegovy® is a medicine with the active substance ‘semaglutide’.
- ‘Active substance’ refers to the main ingredient in a medicine. It is responsible for the way a medicine works
- ‘Semaglutide’ is similar to a natural hormone that your body makes, called glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut after a meal
You can find out more about how Wegovy® works in the body in the ‘How does my medicine work?’ section of this website.
What is Wegovy® used for?
This is not a real patient and is for illustrative purposes only.
Wegovy® can be prescribed in adults for one of the following reasons:
Weight management:
Wegovy® is used for weight loss and weight maintenance along with diet and exercise. It can be prescribed for:
- Adults with obesity (Body Mass Index (BMI)* of 30 kg/m2 or greater)
- Adults with overweight (BMI of 27 kg/m2 and less than 30 kg/m2) and weight-related health problems
*BMI is a measure of your weight in relation to your height.
Risk reduction of serious heart issues in adults (cardiovascular risk reduction):
Wegovy® is used along with diet and exercise to reduce the risk of serious heart issues (heart-related death, heart attacks and strokes) in adults with a history of heart disease (like a heart attack, stroke or poor blood flow to the limbs) and either obesity or overweight (BMI ≥ 27 kg/m2).
Click on the reason you have been prescribed Wegovy® to learn more about your specific need for treatment:
This is not a real patient or healthcare professional and is for illustrative purposes only.
How do I take Wegovy®?
You can find out how to use your Wegovy® FlexTouch® pen, explore tips for remembering to take your medicine and information on how to store and dispose of Wegovy® on the ‘How do I take my medicine?’ page.
Remember that your healthcare team is also there to answer any questions you have.
You should also read the Wegovy® Patient Information Leaflet (PIL) found in the packet of your medicine.
The information on this website does not replace the Patient Information Leaflet (PIL), which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice. Please refer to the PIL found in the product carton for further information on Wegovy®, further information on how to use Wegovy® and a full list of side effects, warnings and precautions.
Reporting side effects
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information promptly. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.